Continuous Glucose Monitoring for the Management of Hyperglycemia in Patients With Glioblastoma

Summary

This clinical trial studies whether continuous glucose monitoring (CGM) can be used to help patients with glioblastoma manage their blood sugar (glucose) levels and improve survival. Glioblastoma is the most common malignant primary brain tumor in adults, with an average survival time of approximately 15-18 months despite therapy. Studies have shown that having a higher-than-normal amount of glucose in the blood (hyperglycemia) during radiation therapy is associated with poorer survival outcomes in glioblastoma patients. Hyperglycemia in glioblastoma patients is often driven by steroids that are commonly used during treatment. CGM uses a device that places a sensor under the skin that monitors glucose levels at regular intervals, providing real-time, or near real-time, glucose information. This can help to identify when a patient has changes in their glucose levels so they may receive necessary interventions or medications sooner. CGM may be an effective way for glioblastoma patients to manage their glucose levels, which may improve survival.

Conditions

• Glioblastoma, IDH-Wildtype
• WHO Grade 4 Glioma

Interventions

OTHER

Best Practice

Receive SOC treatment

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

OTHER

Dietary Intervention

Attend dietary counseling sessions

OTHER

Glucose Measurement

Undergo intermittent glucose monitoring

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

OTHER

Monitoring

Undergo CGM

OTHER

Questionnaire Administration

Ancillary studies

OTHER

Supportive Care

Receive endocrinology-guided interventions

Sponsors & Collaborators

• Mayo Clinic

  lead OTHER

Principal Investigators

• Gelareh Zadeh, MD, PhD · Mayo Clinic in Rochester

Study Design

Allocation

RANDOMIZED

Purpose

SUPPORTIVE_CARE

Masking

SINGLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2025-07-29

Primary Completion

2027-11-30

Completion

2027-11-30

Countries

• United States

Study Locations